The US Food and Drug Administration (FDA) has cleared Oticon Medical, Demant's implants arm, to market and sell its newest bone anchored hearing system (BAHS), a company press release announces.
Oticon's new product, Ponto 5 Superpower, is headed to the market in the coming spring when it will replace its predecessor, Ponto 5 Mini, which was launched by the Demant Group in 2021.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.